Company intelligence / Profile preview

Kadmus Pharmaceuticals, Inc.

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Kadmus Pharmaceuticals developed small molecule therapeutics targeting the endocannabinoid system, particularly through inhibition of FAAH. Its lead compound reached Phase 1 clinical trials for schizophrenia before the company’s core assets and technology were acquired by Organon in 2007. Other programs targeting neuralgia and glaucoma were discontinued prior to acquisition. The company’s research contributed to advancing FAAH inhibitors as a novel therapeutic class with potential applications in CNS disorders and pain management

Therapeutic areas: PsychiatryOphthalmologyNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

University of California Irvine (exclusive license for KDS‑4103/URB597)Organon/Akzo Nobel (acquirer of key assets and staff transfer post-acquisition)

Beyond the preview

Go deeper on Kadmus Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kadmus Pharmaceuticals, Inc..